Oncology Biosimilars Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Oncology Biosimilars Market to 2027 - Global Analysis and Forecasts By Product (Monoclonal Antibodies, Immunomodulators, and Others); Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Brain Cancer, and Others); Distribution Channel (Hospital Pharmacies, Online Pharmacies, And Retail Pharmacies); and Geography

Report Code: TIPRE00002766 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Biosimilars are the fastest-growing class of therapeutic products across the globe. Biosimilars are biologics that serves as interchangeable products offering additional treatment options to a branded drug counterpart, potentially reducing the cost of the prescribed biologics. The biosimilar therapies have been for chronic disease management and supportive care since a few years, however the use of these biosimilars are expected to be applied soon for treatment of various types of cancers referred to as oncology biosimilars.

The market for oncology biosimilars market is expected to witness growth due to extensive research undertaken by market players to bring biosimilars for cancer treatment in the market as well as rapid approval by regulatory authorities for commercialization of these products. However, high costs involved in the research and complexity involved in the formulation of these biologics are likely to hinder market growth.

The "Global Oncology Biosimilars Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a focus on the global market trend. The report aims to provide an overview of global oncology biosimilars market with detailed market segmentation by product, cancer type, and distribution channel. The global oncology biosimilars market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

The global oncology biosimilars market is segmented on the basis of product, cancer type, and distribution channel. On the basis of product, the global oncology biosimilars market is segmented into monoclonal antibodies, Immunomodulators, and others. On the basis of cancer type, the global oncology biosimilars market is segmented in to lung cancer, colorectal cancer, cervical cancer, breast cancer, kidney cancer, stomach cancer, brain cancer, and others. On the basis of distribution channel, the oncology biosimilars market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

The oncology biosimilars market report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global oncology biosimilars market based product, cancer type, and distribution channel. It also provides market size and forecast till 2027 for overall oncology biosimilars market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.

North America dominated the oncology biosimilars market in 2017, owing to the rapid approval of biosimilars by US FDA. Moreover, various market players in the US and Canada have robust pipeline of biosimilars that are expected to be soon approved suggesting high growth rate of the region in the coming years. Asia Pacific on the other hand is expected witness the highest growth over the forecast period owing to the availability of immense opportunities in countries like India, China & Japan. Rising government initiatives for incorporating cost-efficient treatment options for various type of cancer in middle and low income economies of the region are expected to be the driving factors for Asian growth.

The oncology biosimilars market report analyzes factors affecting market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the market in these regions.

The oncology biosimilars market report also includes the profiles of key oncology biosimilars companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years. Some of the key players influencing the market are Biocon, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Amgen Inc., Intas Pharmaceuticals Ltd., Pfizer Inc., Sandoz International GmbH (A Novartis Division), Teva Pharmaceutical Industries Ltd., Mylan N.V., and BIOCAD among others.
Table of Contents

1. INTRODUCTION
1.1. SCOPE OF STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE

2. KEY TAKEAWAYS

3. ONCOLOGY BIOSIMILARS MARKET LANDSCAPE
3.1. MARKET OVERVIEW
3.2. MARKET SEGMENTATION
3.2.1. Oncology Biosimilars Market - By Product
3.2.2. Oncology Biosimilars Market - By Cancer Type
3.2.3. Oncology Biosimilars Market - By Distribution Channel
3.2.3.1. By Country
3.3. PEST ANALYSIS
3.3.1. North America - PEST Analysis
3.3.2. Europe - PEST Analysis
3.3.3. Asia Pacific - PEST Analysis
3.3.4. Middle East and Africa - PEST Analysis
3.3.5. South and Central America- PEST Analysis

4. ONCOLOGY BIOSIMILARS MARKET - KEY INDUSTRY DYNAMICS
4.1. KEY MARKET DRIVERS
4.2. KEY MARKET RESTRAINTS
4.3. KEY MARKET OPPORTUNITIES
4.4. FUTURE TRENDS
4.5. IMPACT ANALYSIS

5. ONCOLOGY BIOSIMILARS MARKET - GLOBAL ANALYSIS
5.1. GLOBAL ONCOLOGY BIOSIMILARS MARKET OVERVIEW
5.2. GLOBAL ONCOLOGY BIOSIMILARS MARKET REVENUE FORECASTS AND ANALYSIS (US$ MN)
5.3. MARKET POSITIONING/MARKET SHARE
5.4. PERFORMANCE OF KEY PLAYERS
5.5. EXPERT OPINIONS

6. ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2027 - BY PRODUCT
6.1. OVERVIEW
6.2. PRODUCT MARKET REVENUE AND FORECASTS ANALYSIS (US$ MN)
6.3. MONOCLONAL ANTIBODIES MARKET
6.3.1. Overview
6.3.2. Monoclonal Antibodies Market Revenue Forecasts and Analysis (US$ Mn)
6.4. IMMUNOMODULATORS MARKET
6.4.1. Overview
6.4.2. Immunomodulators Market Revenue Forecasts and Analysis (US$ Mn)
6.5. OTHERS MARKET
6.5.1. Overview
6.5.2. Others Market Revenue Forecasts and Analysis (US$ Mn)

7. ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2027 - BY CANCER TYPE
7.1. OVERVIEW
7.2. CANCER TYPE MARKET REVENUE AND FORECASTS ANALYSIS (US$ MN)
7.3. LUNG CANCER MARKET
7.3.1. Overview
7.3.2. Lung Cancer Market Revenue Forecasts and Analysis (US$ Mn)
7.4. COLORECTAL CANCER MARKET
7.4.1. Overview
7.4.2. Colorectal Cancer Market Revenue Forecasts and Analysis (US$ Mn)
7.5. CERVICAL CANCER MARKET
7.5.1. Overview
7.5.2. Cervical Cancer Market Revenue Forecasts and Analysis (US$ Mn)
7.6. BREAST CANCER MARKET
7.6.1. Overview
7.6.2. Breast Cancer Market Revenue Forecasts and Analysis (US$ Mn)
7.7. KIDNEY CANCER MARKET
7.7.1. Overview
7.7.2. Kidney Cancer Market Revenue Forecasts and Analysis (US$ Mn)
7.8. STOMACH CANCER MARKET
7.8.1. Overview
7.8.2. Stomach Cancer Market Revenue Forecasts and Analysis (US$ Mn)
7.9. BRAIN CANCER MARKET
7.9.1. Overview
7.9.2. Brain Cancer Market Revenue Forecasts and Analysis (US$ Mn)
7.10. OTHERS MARKET
7.10.1. Overview
7.10.2. Others Market Revenue Forecasts and Analysis (US$ Mn)

8. ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2027 - BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET REVENUE AND FORECASTS ANALYSIS (US$ MN)
8.3. HOSPITAL PHARMACIES MARKET
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Revenue Forecasts and Analysis (US$ Mn)
8.4. ONLINE PHARMACIES MARKET
8.4.1. Overview
8.4.2. Online Pharmacies Market Revenue Forecasts and Analysis (US$ Mn)
8.5. RETAIL PHARMACIES MARKET
8.5.1. Overview
8.5.2. Retail Pharmacies Market Revenue Forecasts and Analysis (US$ Mn)

9. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2027 - COUNTRY ANALYSIS
9.1. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET OVERVIEW
9.2. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE FORECASTS AND ANALYSIS (US$ MN)
9.3. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY PRODUCT (US$ MN)
9.4. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY CANCER TYPE (US$ MN)
9.5. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY DISTRIBUTION CHANNEL (US$ MN)
9.6. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY COUNTRY
9.7. US MARKET OVERVIEW
9.7.1. US Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US$ Mn)
9.7.2. US Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
9.7.3. US Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)
9.8. CANADA MARKET OVERVIEW
9.8.1. Canada Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
9.8.2. Canada Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
9.8.3. Canada Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)
9.9. MEXICO MARKET OVERVIEW
9.9.1. Mexico Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
9.9.2. Mexico Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
9.9.3. Mexico Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)

10. EUROPE ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2027 - COUNTRY ANALYSIS
10.1. EUROPE ONCOLOGY BIOSIMILARS MARKET OVERVIEW
10.2. EUROPE ONCOLOGY BIOSIMILARS MARKET REVENUE FORECASTS AND ANALYSIS (US$ MN)
10.3. EUROPE ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY PRODUCT (US$ MN)
10.4. EUROPE ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY CANCER TYPE (US$ MN)
10.5. EUROPE ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY DISTRIBUTION CHANNEL (US$ MN)
10.6. EUROPE ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY COUNTRY
10.7. FRANCE MARKET OVERVIEW
10.7.1. France Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
10.7.2. France Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
10.7.3. France Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)
10.8. GERMANY MARKET OVERVIEW
10.8.1. Germany Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
10.8.2. Germany Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
10.8.3. Germany Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)
10.9. UK MARKET OVERVIEW
10.9.1. UK Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
10.9.2. UK Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
10.9.3. UK Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)

11. ASIA PACIFIC ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2027 - COUNTRY ANALYSIS
11.1. ASIA PACIFIC ONCOLOGY BIOSIMILARS MARKET OVERVIEW
11.2. ASIA PACIFIC ONCOLOGY BIOSIMILARS MARKET REVENUE FORECASTS AND ANALYSIS (US$ MN)
11.3. ASIA PACIFIC ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY PRODUCT (US$ MN)
11.4. ASIA PACIFIC ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY CANCER TYPE (US$ MN)
11.5. ASIA PACIFIC ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY DISTRIBUTION CHANNEL (US$ MN)
11.6. ASIA PACIFIC ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY COUNTRY
11.7. CHINA MARKET OVERVIEW
11.7.1. China Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
11.7.2. China Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
11.7.3. China Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)
11.8. INDIA MARKET OVERVIEW
11.8.1. India Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
11.8.2. India Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
11.8.3. India Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)
11.9. JAPAN MARKET OVERVIEW
11.9.1. Japan Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
11.9.2. Japan Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
11.9.3. Japan Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)

12. MIDDLE EAST AND AFRICA (MEA) ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2027 - COUNTRY ANALYSIS
12.1. MIDDLE EAST AND AFRICA (MEA) ONCOLOGY BIOSIMILARS MARKET OVERVIEW
12.2. MIDDLE EAST AND AFRICA (MEA) ONCOLOGY BIOSIMILARS MARKET REVENUE FORECASTS AND ANALYSIS (US$ MN)
12.3. MIDDLE EAST AND AFRICA (MEA) ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY PRODUCT (US$ MN)
12.4. MIDDLE EAST AND AFRICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY CANCER TYPE (US$ MN)
12.5. MIDDLE EAST AND AFRICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY DISTRIBUTION CHANNEL (US$ MN)
12.6. MIDDLE EAST AND AFRICA (MEA) ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY COUNTRY
12.7. SOUTH AFRICA MARKET OVERVIEW
12.7.1. South Africa Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
12.7.2. South Africa Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
12.7.3. South Africa Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)
12.8. SAUDI ARABIA MARKET OVERVIEW
12.8.1. Saudi Arabia Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
12.8.2. Saudi Arabia Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
12.8.3. Saudi Arabia Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)
12.9. UAE MARKET OVERVIEW
12.9.1. UAE Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
12.9.2. UAE Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
12.9.3. UAE Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)

13. SOUTH AND CENTRAL AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2027 - COUNTRY ANALYSIS
13.1. SOUTH AND CENTRAL AMERICA ONCOLOGY BIOSIMILARS MARKET OVERVIEW
13.2. SOUTH AND CENTRAL AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE FORECASTS AND ANALYSIS (US$ MN)
13.3. SOUTH AND CENTRAL AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY PRODUCT (US$ MN)
13.4. SOUTH AND CENTRAL AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY CANCER TYPE (US$ MN)
13.5. SOUTH AND CENTRAL AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY DISTRIBUTION CHANNEL (US$ MN)
13.6. SOUTH AND CENTRAL AMERICA ONCOLOGY BIOSIMILARS MARKET REVENUE AND FORECASTS ANALYSIS - BY COUNTRY
13.7. BRAZIL MARKET OVERVIEW
13.7.1. Brazil Oncology Biosimilars Market Revenue and Forecasts Analysis - By Product (US $ Mn)
13.7.2. Brazil Oncology Biosimilars Market Revenue and Forecasts Analysis - By Cancer Type (US$ Mn)
13.7.3. Brazil Oncology Biosimilars Market Revenue and Forecasts Analysis - By Distribution Channel (US$ Mn)

14. INDUSTRY LANDSCAPE
14.1. ORGANIC GROWTH STRATEGIES
14.1.1. New Product Launches
14.1.2. Marketing & Promotional Activities
14.2. INORGANIC GROWTH STRATEGIES
14.2.1. Partnerships, Collaborations, and Joint Ventures
14.2.2. Mergers & Acquisitions

15. ONCOLOGY BIOSIMILARS MARKET, KEY COMPANY PROFILES
15.1. BIOCON
15.1.1. Key Facts
15.1.2. Business Description
15.1.3. Financial Overview
15.1.4. Product Portfolio
15.1.5. SWOT Analysis
15.1.6. Key Developments
15.2. CELLTRION INC.
15.2.1. Key Facts
15.2.2. Business Description
15.2.3. Financial Overview
15.2.4. Product Portfolio
15.2.5. SWOT Analysis
15.2.6. Key Developments
15.3. DR. REDDY’S LABORATORIES LTD.
15.3.1. Key Facts
15.3.2. Business Description
15.3.3. Financial Overview
15.3.4. Product Portfolio
15.3.5. SWOT Analysis
15.3.6. Key Developments
15.4. AMGEN INC.
15.4.1. Key Facts
15.4.2. Business Description
15.4.3. Financial Overview
15.4.4. Product Portfolio
15.4.5. SWOT Analysis
15.4.6. Key Developments
15.5. PFIZER INC.
15.5.1. Key Facts
15.5.2. Business Description
15.5.3. Financial Overview
15.5.4. Product Portfolio
15.5.5. SWOT Analysis
15.5.6. Key Developments
15.6. INTAS PHARMACEUTICALS LTD.
15.6.1. Key Facts
15.6.2. Business Description
15.6.3. Financial Overview
15.6.4. Product Portfolio
15.6.5. SWOT Analysis
15.6.6. Key Developments
15.7. SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
15.7.1. Key Facts
15.7.2. Business Description
15.7.3. Financial Overview
15.7.4. Product Portfolio
15.7.5. SWOT Analysis
15.7.6. Key Developments
15.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
15.8.1. Key Facts
15.8.2. Business Description
15.8.3. Financial Overview
15.8.4. Product Portfolio
15.8.5. SWOT Analysis
15.8.6. Key Developments
15.9. MYLAN N.V.
15.9.1. Key Facts
15.9.2. Business Description
15.9.3. Financial Overview
15.9.4. Product Portfolio
15.9.5. SWOT Analysis
15.9.6. Key Developments
15.10. BIOCAD
15.10.1. Key Facts
15.10.2. Business Description
15.10.3. Financial Overview
15.10.4. Product Portfolio
15.10.5. SWOT Analysis
15.10.6. Key Developments

16. APPENDIX
16.1. ABOUT THE INSIGHT PARTNERS
16.2. GLOSSARY OF TERMS
16.3. RESEARCH METHODOLOGY
The List of Companies

1. BIOCON
2. CELLTRION INC.
3. DR. REDDY'S LABORATORIES LTD.
4. AMGEN INC.
5. PFIZER INC.
6. INTAS PHARMACEUTICALS LTD.
7. SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
9. MYLAN N.V.
10. BIOCAD